The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on February 14, 2025. The analyst firm set a price target for $26.00 expecting TXG to rise to within 12 months (a possible 142.54% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Morgan Stanley, and 10x Genomics maintained their overweight rating.

The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.

The last downgrade for 10x Genomics Inc happened on February 13, 2025 when Leerink Partners changed their price target from $25 to $12 for 10x Genomics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $28.00 to $26.00. The current price 10x Genomics (TXG) is trading at is $10.72, which is out of the analyst’s predicted range.